Provided by Tiger Fintech (Singapore) Pte. Ltd.

NeoGenomics

9.83
+0.30503.20%
Post-market: 9.830.00000.00%17:23 EDT
Volume:1.18M
Turnover:11.65M
Market Cap:1.26B
PE:-15.81
High:9.99
Open:9.68
Low:9.60
Close:9.52
Loading ...

Company Profile

Company Name:
NeoGenomics
Exchange:
NASDAQ
Establishment Date:
2001
Employees:
2200
Office Location:
9490 NeoGenomics Way,Fort Myers,Florida,United States
Zip Code:
33912
Fax:
239 690 4237
Introduction:
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Directors

Name
Position
Douglas M. VanOort
Chairman of the Board of Directors and Chief Executive Officer
Steven C. Jones
Director,Executive Vice President
Alison L. Hannah
Director
Bruce K. Crowther
Director
Kevin C. Johnson
Director
Kieran P. Murphy
Director
Lynn A. Tetrault
Director
Raymond R. Hipp
Director
William J. Robison
Director

Shareholders

Name
Position
Douglas M. VanOort
Chairman of the Board of Directors and Chief Executive Officer
George A. Cardoza
Chief Financial Officer
Edwin F. Weidig III
Vice President of Finance and Principal Accounting Officer
Jennifer Balliet
Chief Culture Officer,Vice President of Human Resources
Maher Albitar
Chief Medical Officer
Robert J. Shovlin
President of Clinical Services Division
Steven A. Ross
Chief Information Officer
Steven Brodie
Vice President of Operations
Steven C. Jones
Director,Executive Vice President